Search
Patexia Community

Innovation, Technology, and IP News

CAFC's Evolving Stance on Patent Eligibility: Implications for Appeals

The United States Court of Appeals for the Federal Circuit (CAFC) has been at the forefront of shaping patent law in the United States. Among the many facets of patent law that CAFC...

Major Med Device Product Developer GE HealthCare Collaborating with Healthcare Providers

Written by: Kregg Koch For good reasons, including product safety, quality assurance, development of delivery procedures and instructions, it has been a common practice for medical...

Fresh From the Bench: Latest Precedential Patent Cases

CASE OF THE WEEK Baxalta Inc. v. Genentech, Inc., Appeal No. 22-1461 (Fed. Cir. Sept. 20, 2023) Our Case of the Week focuses on the enablement requirement. It’s the first case...

Enter TitleFederal Circuit Revisits Standard for Enablement of Antibody Claims

Written by: Ashley C. Morales & Joseph Mallon, Ph.D. In Baxalta Incorporated v. Genentech, Inc., 2022-1461, the Federal Circuit affirmed the district court’s decision...

Fresh From the Bench: Latest Precedential Patent Cases

CASE OF THE WEEK Columbia Sportswear North America, Inc. v. Seirus Innovative Accessories, Inc., Appeal Nos. 2021-2299, -2338 (Fed. Cir. Sept. 15, 2023) In a decade-old case that has ...

Prosecution History May Support a Motivation to Combine

Written by: Rhett D. Ramsey & Jacob R. Rosenbaum Elekta Limited v. Zap Surgical Systems, Inc. Before: Reyna, Stoll, and Stark. Appeal from the Patent Trial and Appeal Board. ...

Feed tagged as "hatch-waxman":
We are proud to announce that tomorrow marks the release of the fourth edition of our ANDA Litigation Intelligence Report. This year's report... Read More »
In the intricate world of pharmaceuticals, where innovation meets regulation, ANDA litigation stands as a pivotal battleground... Read More »
In the realm of pharmaceuticals, the approval process for generic and brand-name drugs holds significant importance. The Hatch-Waxman Act, ... Read More »
Abbreviated New Drug Application (ANDA) litigation stands at the crossroads of pharmaceutical innovation and legal prowess. As generic... Read More »
In the world of pharmaceuticals, access to affordable generic drugs is crucial for ensuring cost-effective healthcare solutions. The Drug... Read More »
When it comes to generic medications, the Abbreviated New Drug Application (ANDA) process plays a crucial role in bringing affordable... Read More »
When it comes to preparing an Abbreviated New Drug Application (ANDA), there are several common pitfalls that applicants often encounter... Read More »
The Abbreviated New Drug Application (ANDA) process plays a vital role in the pharmaceutical industry, enabling generic drug manufacturers ... Read More »
The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act, revolutionized the pharmaceutical... Read More »
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought battle ... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report, covering important statistics and evaluating all stakeholders in ... Read More »
Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused on... Read More »
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by providing... Read More »
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman... Read More »
In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to the market. At that... Read More »
  Small molecule drugs have been the norm for much of medicine’s history. Only in the past decade has there been a rise ... Read More »
Earlier in August, we released our second ANDA Litigation Intelligence Report. We analyzed all parties involved in Hatch-Waxman cases and ranked the top law firms and ... Read More »
In late August, we released our second annual ANDA Litigation Intelligence Report where we evaluated all stakeholders in Hatch-Waxman cases including ANDA attorneys... Read More »
A couple of weeks ago we released our second annual ANDA Litigation Intelligence Report where we covered the rankings, statistics, and comprehensive analysis of... Read More »
Comments
vagisha singhNice points mention in this post and it was very usefull post ,thanks for post
Sep 4, 2021
vagisha singhit is nice and usefull post .thank you for post
Sep 4, 2021
Show more Newsfeed posts
Menu